Bilateral Comparison of Treatment of Facial Actinic Keratoses Using Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Incubation Times
| Status: | Completed |
|---|---|
| Conditions: | Dermatology |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/20/2017 |
| Start Date: | October 2015 |
| End Date: | April 13, 2017 |
A Randomized, Evaluator-blinded, Bilateral Comparison of the Treatment of Facial Actinic Keratoses Using Combination Microneedling and Photodynamic Therapy With Aminolevulinic Acid and Blue Light Versus Photodynamic Therapy With Aminolevulinic Acid and Blue Light Using Two Different Incubation Times
This is an investigator initiated, two center, randomized, evaluator-blinded, bilateral
(right vs. left) study of photodynamic therapy in subjects with facial actinic keratoses.
Subject's face will be randomized to receive one of four treatments: Treatment 1, Treatment
2, Treatment 3 or Treatment 4. Treatment 1 will include microneedling performed prior to ALA
application to their right face and ALA application only to the left face 60 minutes prior to
BLUE light treatment for 1000 seconds (16 minutes 40 seconds). Treatment 2 will include
microneedling performed prior to ALA application to their left face and ALA application only
to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16
minutes 40 seconds). Treatment 3 will include microneedling performed prior to ALA
application to their right face and ALA application only to the left side of their face 30
minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds). Treatment 4
will include microneedling performed prior to ALA application to their left face and ALA
application only to the right side of their face 30 minutes prior to BLUE light treatment for
1000 seconds (16 minutes 40 seconds). The face is defined as the surface of the skin
encompassing the forehead to the hair line and tops of the eyebrows, the entire nasal dorsum,
the cheeks (bounded by the orbital rim, the anterior border of the ear, the jawline, the nose
and the chin), the upper lip (not including the vermilion border) and the chin (bounded by
the lower edge of the vermilion border, the cheek junction and the jawline). The treatment
areas will be not be occluded. A line will be drawn with a marker that intersects the nose,
forehead, upper lip and chin in the midline. The left face is defined as the face to the left
of this line and the right face is defined as the face to the right of this line.
Posttreatment follow-up visits will be scheduled to occur 48 hours after the treatment and at
1, 3 and 6 months after the treatment. A blinded evaluator who will remain blinded with
respect to the randomization will conduct grading of the subject's actinic keratoses and
photodamage. Tolerability of treatment will be assessed by evaluations of the local skin
response (erythema, edema, etc.) and will be conducted by an unblinded evaluator.
Safety will be evaluated by adverse events and local skin responses reported during the study
(right vs. left) study of photodynamic therapy in subjects with facial actinic keratoses.
Subject's face will be randomized to receive one of four treatments: Treatment 1, Treatment
2, Treatment 3 or Treatment 4. Treatment 1 will include microneedling performed prior to ALA
application to their right face and ALA application only to the left face 60 minutes prior to
BLUE light treatment for 1000 seconds (16 minutes 40 seconds). Treatment 2 will include
microneedling performed prior to ALA application to their left face and ALA application only
to the right side of their face 60 minutes prior to BLUE light treatment for 1000 seconds (16
minutes 40 seconds). Treatment 3 will include microneedling performed prior to ALA
application to their right face and ALA application only to the left side of their face 30
minutes prior to BLUE light treatment for 1000 seconds (16 minutes 40 seconds). Treatment 4
will include microneedling performed prior to ALA application to their left face and ALA
application only to the right side of their face 30 minutes prior to BLUE light treatment for
1000 seconds (16 minutes 40 seconds). The face is defined as the surface of the skin
encompassing the forehead to the hair line and tops of the eyebrows, the entire nasal dorsum,
the cheeks (bounded by the orbital rim, the anterior border of the ear, the jawline, the nose
and the chin), the upper lip (not including the vermilion border) and the chin (bounded by
the lower edge of the vermilion border, the cheek junction and the jawline). The treatment
areas will be not be occluded. A line will be drawn with a marker that intersects the nose,
forehead, upper lip and chin in the midline. The left face is defined as the face to the left
of this line and the right face is defined as the face to the right of this line.
Posttreatment follow-up visits will be scheduled to occur 48 hours after the treatment and at
1, 3 and 6 months after the treatment. A blinded evaluator who will remain blinded with
respect to the randomization will conduct grading of the subject's actinic keratoses and
photodamage. Tolerability of treatment will be assessed by evaluations of the local skin
response (erythema, edema, etc.) and will be conducted by an unblinded evaluator.
Safety will be evaluated by adverse events and local skin responses reported during the study
Inclusion Criteria:
- Subject is male or non-pregnant female over the age of 18 years. Females must be
post-menopausal, surgically sterile or using a medically acceptable form of birth
control, with a negative urine pregnancy test at the Baseline visit.
- Subject has provided written and verbal informed consent.
- Subject has four (4) or more AK lesions on each side of the face.
- Subject is willing to comply with study instructions and return to the clinic for
required visits.
- Subject has Fitzpatrick skin type I-IV
Exclusion Criteria:
- Subject is pregnant, lactating, or is planning to become pregnant during the study.
- Subject has a history of cutaneous photosensitization, porphyria, hypersensitivity to
porphyrins or photodermatosis or any condition with associated immunosuppression (e.g.
HIV, systemic malignancy, etc.).
- Subject has any skin pathology or condition that could interfere with the evaluation
of the test product or requires the use of interfering topical or systemic therapy.
- Subject has any condition, which, in the investigator's opinion, would make it unsafe
for the subject to participate in this research study.
- Subject has Fitzpatrick skin type V - VI.
- Subject is currently enrolled in an investigational drug or device study.
- Subject has received an investigational drug or been treated with an investigational
device within 30 days prior to the initiation of treatment (baseline).
- Subject is unable to communicate or cooperate with the investigator due to language
problems, poor mental development, or impaired cerebral function.
- Subject may be unreliable for the study including subjects who engage in excessive
alcohol intake or drug abuse, or subjects who are unable to return for scheduled
follow-up visits.
- Subject has a known sensitivity to one or more of the vehicle components (ethyl
alcohol, isopropyl alcohol, laureth 4, polyethylene glycol).
- Subject has the need to be exposed to artificial tanning devices or excessive sunlight
during the trial.
- Subject has used any of the following topical preparations on the area(s) to be
treated
- Keratolytics including urea (greater than 5%), alpha hydroxyacids [e.g. glycolic acid,
lactic acid, etc. greater than 5%], salicylic acid (greater than 2%) within 2 days of
initiation of treatment.
- Retinoids, including tazarotene, adapalene, tretinoin, retinol, within 4 weeks of the
initiation of treatment.
- Cryotherapy, dicofenac or other treatments for AK within 8 weeks of initiation of
treatment
- Microdermabrasion, laser ablative treatments or chemical peels within 8 weeks of the
initiation of treatment.
- 5-FU, imiquimod or ALA-PDT within 6 months of initiation of treatment.
- Subject has used any of the following systemic medications:
- Immuno-suppressants including steroids, chemotherapy, etc. within 3 months of the
initiation of treatment
- Retinoid therapy within 6 months of the initiation of treatment.
We found this trial at
1
site
Charlotte, North Carolina 28207
Phone: 704-375-6766
Click here to add this to my saved trials
